Advertisement
Commentary| Volume 54, ISSUE 6, P541-549, June 2001

Download started.

Ok

The double-blind, randomized, placebo-controlled trial

Gold standard or golden calf?

      Abstract

      The double-blind randomized controlled trial (RCT) is accepted by medicine as objective scientific methodology that, when ideally performed, produces knowledge untainted by bias. The validity of the RCT rests not just on theoretical arguments, but also on the discrepancy between the RCT and less rigorous evidence (the difference is sometimes considered an objective measure of bias). A brief overview of historical and recent developments in “the discrepancy argument” is presented. The article then examines the possibility that some of this “deviation from truth” may be the result of artifacts introduced by the masked RCT itself. Can an “unbiased” method produce bias? Among the experiments examined are those that augment the methodological stringency of a normal RCT in order to render the experiment less susceptible to subversion by the mind. This methodology, a hypothetical “platinum” standard, can be used to judge the “gold” standard. The concealment in a placebo-controlled RCT seems capable of generating a “masking bias.” Other potential biases, such as “investigator self-selection,” “preference,” and “consent” are also briefly discussed. Such potential distortions indicate that the double-blind RCT may not be objective in the realist sense, but rather is objective in a “softer” disciplinary sense. Some “facts” may not exist independent of the apparatus of their production.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rorty R.
        Philosophy and the mirror of nature. Princeton University Press, Princeton1977
        • Friedman L.M.
        • Furberg C.D.
        • DeMets D.L.
        Fundamentals of clinical trials. Mosby, St. Louis1985
        • Weinstein M.C.
        Allocation of subjects in medical experiments.
        N Engl J Med. 1974; 291: 1278-1285
        • Fisher S.
        • Cole J.O.
        • Rickels K.
        • Uhlenhutt E.H.
        Drug-set interaction.
        in: Bradley P.B. Flügel F. Hoch P.H. Neuropsychopharmacology vol. 3. Elsevier, New York1964
        • Kaptchuk T.J.
        Intentional ignorance.
        Bull Hist Med. 1998; 72: 389-433
        • Gehan E.A.
        • Freireich E.J.
        Non-randomized controls in cancer clinical trials.
        N Engl J Med. 1974; 290: 198-203
        • Kleijnen J.
        • de Craen A.J.M.
        • van Everdingen J.
        • Krol L.
        Placebo effect in double-blind clinical trials.
        Lancet. 1994; 344: 1347-1349
        • Sibbald B.
        • Roland M.
        Why are randomized controlled trials important?.
        Br Med J. 1998; 316: 201-202
        • Schulz K.F.
        • Chalmers I.
        • Hayes R.J.
        • Altman D.G.
        Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials.
        J Am Med Assoc. 1995; 273: 408-412
        • Sackett D.L.
        Rules of evidence and clinical recommendations on the use of antithrombotic agents.
        Chest. 1986; 89: 2S-3S
        • Pocock S.J.
        Allocation of patients to treatment in clinical trials.
        Biometrics. 1979; 35: 183-197
        • Greiner T.
        • Gold H.
        • Cattell M.
        • Travell J.
        • Bakst H.
        • Rinzler S.H.
        • Benjamin Z.H.
        • Warshaw L.J.
        • Bobb A.L.
        • Kwit N.T.
        • Modell W.
        • Rothendler H.H.
        • Messeloff C.R.
        • Kramer M.L.
        A method for the evaluation of the effects of drugs on cardiac pain in patients with angina on effort. A study of Khellin (Visammin).
        Am J Med. 1950; 9: 143-155
      1. Conference on Therapy. How to Evaluate a New Drug. Am J Med 1954;17:722–7.

        • Foulds G.A.
        Clinical research in psychiatry.
        J Ment Sci. 1958; 104: 259-265
        • Glick B.S.
        • Margolis R.
        A study of the influence of experimental design on clinical outcome in drug research.
        Am J Psychol. 1962; 118: 1087-1096
        • Astin A.
        • Ross S.
        Glutamic acid and human intelligence.
        Psychol Bull. 1960; 57: 429-434
        • Wechsler H.
        • Grosser G.H.
        • Greenblatt M.
        Research evaluating antidepressant medications on hospitalized mental patients.
        J Nerve Ment Dis. 1965; 141: 231-239
        • Grace N.D.
        • Muench H.
        • Chalmer T.C.
        The present status of shunts for portal hypertension in cirrhosis.
        Gastroenterology. 1996; 50: 684-691
        • O'Brien W.M.
        Indomethacin.
        Clin Pharm Ther. 1967; 9: 94-107
        • Kaptchuk T.J.
        Powerful placebo.
        Lancet. 1998; 351: 1722-1725
        • Kunz R.
        • Oxman A.D.
        The unpredictability paradox.
        Br Med J. 1998; 317: 1185-1190
        • Chalmers T.C.
        • Matta R.J.
        • Smith H.
        • Kunzler A.M.
        Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction.
        N Engl J Med. 1977; 297: 1091-1096
        • Sacks H.
        • Chalmers T.C.
        • Smith H.
        Randomized versus historical controls for clinical trials.
        Am J Med. 1982; 72: 233-240
        • Diehl L.F.
        • Perry D.J.
        A comparison of randomized concurrent control groups with matched historical control groups.
        J Clin Oncol. 1986; 4: 1114-1120
        • Pyorala S.
        • Huttunen N.P.
        • Uhari M.
        A review and meta analysis of hormonal treatment of cryptorchidism.
        J Clin Endocrinol Metab. 1995; 80: 2795-2799
        • Carroll D.
        • Tramer M.
        • McQuay H.
        • Nye B.
        • Moore A.
        Randomization is important in studies with pain outcomes.
        Br J Med. 1996; 77: 798-803
        • Reimold S.C.
        • Chalmers T.C.
        • Berlin J.A.
        • Antman E.M.
        Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation.
        Am Heart J. 1992; 124: 924-932
        • Recurrent Miscarriage Immunotherapy Trialists Group
        Worldwide collaborative observational study and meta-analysis on allogenic leukocyte immunotherapy for recurrent spontaneous abortion.
        Am J Reprod Immunol. 1994; 32: 55-72
        • Watson A.
        • Vanderkerckhove P.
        • Lilford R.
        • Vail A.
        • Brosens I.
        • Hughes E.
        A meta-analysis of the therapeutic role of oil soluble contrast media at hysterosalpingography.
        Fertil Steril. 1994; 61: 470-477
        • Colditz G.A.
        • Miller J.N.
        • Mosteller F.
        How study design affects outcomes in comparisons of therapy. I.
        Stat Med. 1989; 8: 441-454
        • Miller J.N.
        • Colditz G.A.
        • Mosteller F.
        How study design affects outcomes in comparisons of therapy. II.
        Stat Med. 1989; 8: 455-466
        • Ottenbacher K.
        Impact of random assignment on study outcome.
        Control Clin Trials. 1992; 13: 50-61
        • McKee M.
        • Gritton A.
        • Black N.
        • McPherson K.
        • Sanderson C.
        • Bain C.
        Interpreting the evidence.
        Br Med J. 1999; 319: 312-315
        • Reeves B.C.
        • MacLehose R.R.
        • Harvey I.M.
        • Sheldon T.A.
        • Russell I.T.
        • Black A.M.A.
        Comparison of effect size estimates derived from randomised and non-randomised studies.
        in: Black N. Brazier J. Fitzpatrick R. Reeves B. Health services research methods a guide to best practice. BMJ Publishing, London1998
      2. Britton A, McKee M, Black N, McPherson K, Sanderson C, Bain C. Three systematic reviews—not so different answers? [Letter] eBMJ. http://www.bmj.org/cgi/eletters/319/7205/312.

        • Concato J.
        • Shah N.
        • Horwitz R.I.
        Randomized, controlled trials, observational studies, and the hierarchy of research designs.
        N Engl J Med. 2000; 342: 1887-1892
        • Benson K.
        • Hartz A.J.
        A comparison of observational studies and randomized, controlled trials.
        N Engl J Med. 2000; 342: 1878-1888
        • Pocock S.J.
        • Elbourne D.R.
        Randomized trials or observational tribulations.
        N Engl J Med. 2000; 342: 1907-1909
      3. Kunz R, Oxman A. Two systematic reviews-two different answers? [Letter] eBMJ. http://www.bmj.org/cgi/eletters/319/7205/312.

        • Moher D.
        • Ba'Pham Jones A.
        • Cook D.J.
        • Jadad A.R.
        • Moher M.
        • Tugwell P.
        • Klassen T.P.
        Does the quality of randomized trials affect estimates of intervention efficacy reported in meta-analysis?.
        Lancet. 1998; 352: 609-613
        • Chalmers T.C.
        • Celano P.
        • Sacks H.S.
        • Smith H.
        Bias in treatment assignment in controlled clinical trials.
        N Engl J Med. 1983; 309: 1358-1361
        • Hacking I.
        Statistical language, statistical truth and statistical reason.
        in: McMullin E. The social dimensions of science. University of Notre Dame Press, Notre Dame1992
        • Sacks H.S.
        • Chalmers T.C.
        • Smith H.
        Sensitivity and specificity of clinical trials. Randomized v historical controls.
        Arch Intern Med. 1983; 143: 753-755
        • Black N.
        Why we need observational studies to evaluate the effectiveness of health care.
        Br Med J. 1996; 312: 1215-1218
        • McPherson K.
        The best and the enemy of the good.
        J Epidemiol Comm Health. 1994; 48: 6-15
        • Schulz K.F.
        Subverting randomization on controlled trials.
        J Am Med Assoc. 1995; 274: 1456-1458
        • Torgerson D.J.
        • Sibbald B.
        What is a patient preference trial?.
        Br Med J. 1998; 316: 360
        • Silverman W.A.
        • Altman D.G.
        Patients' preferences and randomized trials.
        Lancet. 1996; 347: 171-174
        • Urbach P.
        Randomization and the design of experiments.
        Philos Science. 1985; 52: 256-273
        • Kempthorne O.
        Why randomize?.
        J Stat Plan Inf. 1977; 1: 1-25
        • Dahan R.
        • Caulin C.
        • Figea L.
        • Kanis J.A.
        • Cauline R.
        • Segrestaa J.M.
        Does informed consent influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in patients admitted to hospital.
        Br Med J. 1986; 293: 363-364
        • Bergmann J.F.
        • Chassany O.
        • Gandiol J.
        • Deblois P.
        • Kanis J.A.
        • Segrestaa J.M.
        • Caulin C.
        • Dahan R.
        A randomized clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain.
        Clin Trials Meta-Anal. 1994; 29: 41-47
        • Roethlisberger F.J.
        • Dickson W.J.
        • Wright H.A.
        Management and the worker. Harvard University Press, Cambridge1946
      4. Bouchet C, Guillemin F, Briançon S. Nonspecific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996;1996:49:15–20.

        • Kirsch I.
        • Weixel L.J.
        Double-blind versus deceptive administration of a placebo.
        Behav Neurosci. 1988; 2: 319-323
        • Hughes J.R.
        • Gulliver S.B.
        • Amori G.
        • Mireault G.C.
        • Fenwsick J.F.
        Effect of instructions and nicotine on smoking cessation, withdrawal symptoms and self-administration of nicotine gum.
        Psychopharmacology. 1989; 99: 486-491
        • Kirsch I.
        • Rosadino M.J.
        Do double-blind studies with informed consent yield externally valid results?.
        Psychopharmacology. 1993; 110: 437-442
        • Dinnerstein A.J.
        • Lowenthal M.
        • Blitz B.
        The interaction of drugs with placebos in the control of pain and anxiety.
        Perspect Biol Med. 1966; 10: 103-114
        • Penick S.B.
        • Hinkle L.E.
        The effect of expectation on response to phenmetrazine.
        Psychosom Med. 1964; 26: 369-373
        • Penick S.G.
        • Fisher S.
        Drug-set interaction.
        Psychosom Med. 1965; 27: 177-182
        • Lyerly S.B.
        • Ross S.
        • Krugman A.D.
        • Cylde D.J.
        Drugs and placebos.
        J Abnorm Soc Psychol. 1964; 68: 321-327
        • Luparello T.J.
        • Leist N.
        • Lourie C.H.
        • Sweet P.
        The interaction of psychologic stimuli and pharmacologic agents on airway reactivity in asthmatic subjects.
        Psychosom Med. 1970; 32: 509-513
        • Sodergren S.C.
        • Hyland M.E.
        Expectancy and asthma.
        in: Kirsch I. How expectations shape experience. American Psychological Association, Washington, DC1999
        • Kirsch I.
        Response expectancy as a determinant of experience and behavior.
        Am Psychol. 1985; 40: 1189-1202
        • Hull J.C.
        • Bond C.F.
        Social and behavioral consequences of alcohol consumption and expectancy.
        Psychol Bull. 1986; 99: 347-360
        • Wolf S.
        Effects of suggestion and conditioning on the action of chemical agents in human subjects—the pharmacology of placebos.
        J Clin Invest. 1950; 29: 100-109
        • Britton A.
        • McKee M.
        • Black N.
        • McPherson K.
        • Sanderson C.
        • Bain C.
        Choosing between randomised and non-randomised studies.
        Health Technol Assess. 1998; 2: 1-124
        • Wolf S.
        Part IV. Placebos.
        Clin Pharmacol Ther. 1962; 3: 254-257
        • Sarles H.
        • Camatte R.
        • Sahel J.
        A study of the variations in the response regarding duodenal ulcer when treated with placebo by different investigators.
        Digestion. 1977; 16: 289-292
        • Joyce C.R.B.
        Differences between physicians as revealed by clinical trials.
        Proc Soc Med. 1961; 28: 12-14
        • Thomas K.B.
        General practice consultations.
        Br Med J. 1987; 294: 1200-1202
        • LeBaron S.
        • Reyher J.
        • Stack J.M.
        Paternalistic vs. egalitarian physician styles.
        J Fam Med. 1985; 21: 56-62
        • Uhlenhuth E.H.
        • Canter A.
        • Neustadt J.O.
        • Payson H.E.
        The symptomatic relief of anxiety with meprobamate, phenobarbital and placebo.
        Am J Psychiatry. 1959; 115: 905-910
        • Uhlenhuth E.H.
        • Rickels K.
        • Fisher S.
        • Park L.C.
        • Lipman R.S.
        • Mock J.
        Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy.
        Psychopharmacologia (Berl). 1966; 9: 392-418
        • Martindale C.
        The therapist-as-fixed-effect fallacy in psychotherapy research.
        J Controlled Clin Psychol. 1978; 46: 1526-1530
        • Shapiro A.K.
        • Shapiro E.
        The powerful placebo. The Johns Hopkins University Press, Baltimore1997
        • Siegrist J.
        • Peter R.
        • Junge A.
        • Cremer P.
        • Seidel D.
        Low status control, high effect at work and ischaemic heart disease.
        Soc Sci Med. 1990; 31: 1127-1234
        • Horwitz R.I.
        • Viscolli C.M.
        • Berkman L.
        • Donaldson R.M.
        • Horwitz S.M.
        • Murray C.J.
        • Ransohoff D.F.
        • Sindelar J.
        Treatment adherence and risk of death after a myocardial infarction.
        Lancet. 1991; 336: 543-545
        • Horwitz R.I.
        • Horwitz S.M.
        Adherence to treatment and health outcomes.
        Arch Intern Med. 1993; 153: 1863-1868
        • Brewin C.R.
        • Bradley C.
        Patient preferences and randomised clinical trials.
        Br Med J. 1989; 299: 313-315
        • Feinstein A.R.
        Statistics versus science in the design of experiments.
        Clin Pharm Ther. 1970; 11: 282-292
        • MIAMI Trial Research Group
        Patient population.
        Am J Cardiol. 1985; 56: 10G-14G
        • Smith P.
        • Arnesen H.
        Mortality in non-consenters in a post-myocardial infarction trial.
        J Int Med. 1990; 228: 253-256
        • Fairhurst K.
        • Dowrick C.
        Problems with recruitment in a randomized controlled trial of counselling in general practice.
        J Health Serv Res Policy. 1996; 1: 77-80
        • Llewellyn-Thomas H.A.
        • McGreal M.J.
        • Thiel E.C.
        • Fine S.
        • Erlichman C.
        Patients' willingness to enter clinical trials.
        Soc Sci Med. 1991; 32: 35-42
        • Charlson M.E.
        • Horwitz R.I.
        Applying results of randomised trials to clinical practice.
        Br Med J. 1984; 289: 1281-1284
        • Schooler N.R.
        How generalizable are the results of clinical trials?.
        Psychopharmacol Bull. 1980; 16: 29-31
        • Marcus S.M.
        Assessing non-consent bias with parallel randomized and nonrandomized clinical trials.
        J Clin Epidemiol. 1997; 50: 823-828
        • Pringle M.
        • Churchill R.
        Randomised controlled trials in general practice. Gold standard or fool's gold?.
        Br Med J. 1995; 311: 1382-1383
        • Schooler N.R.
        • Levine J.
        • Severe J.B.
        • Brauzer B.
        Prevention of relapse in schizophrenia.
        Arch Gen Psychol. 1980; 37: 16-24
        • Edlund J.M.
        • Craig T.J.
        • Richardson M.A.
        Informed consent as a form of volunteer bias.
        Am J Psychol. 1985; 142–624–7
        • Levine R.J.
        The apparent incompatibility between informed consent and placebo-controlled clinical trials.
        Clin Pharmacol Ther. 1987; 42: 247-249
        • Myers M.G.
        • Cairns J.A.
        • Singer J.
        The consent form as a possible cause of side effects.
        Clin Pharmacol Ther. 1987; 42: 250-253
        • Simes R.J.
        • Tattershall M.H.N.
        • Coastes A.S.
        • Raghavan D.
        • Solomon H.J.
        Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer.
        Br Med J. 1986; 293: 1065-1068
        • Porter T.M.
        Objectivity as standardization.
        Ann Scholar. 1992; 9: 19-60
        • Mathews J.R.
        Quantification and the quest for medical certainty. Princeton University Press, Princeton1995
        • Megill A.
        Introduction.
        in: Megill A. Rethinking objectivity. Duke University Pres, Durham1994
        • Putnam H.
        Reason, truth, and history. Cambridge University Press, Cambridge1981
        • Feinstein A.R.
        Meta-analysis.
        J Clin Epidemiol. 1995; 48: 71-79